Pfizer is shaking up its corporate structure again as it prepares to merge with Allergan and further lays the groundwork for a potential split in a few years. The structural rejig pushes out Geno Germano, who has been leading Pfizer's global innovative pharma business, and elevates one top Allergan manager, Bill Meury, to the combined company's commercial leadership team.
Vertex has so far had a lot of success widening the patient pool for orphan drug Kalydeco. But in its latest quest for a label expansion, the FDA has stopped it in its tracks. Read more >>
Pharma eyes are watching Capitol Hill on Thursday, where drug-price hikes will go on trial in a much-publicized congressional committee hearing. Valeant interim CEO Howard Schiller and ex-Turing Pharmaceuticals chief Martin Shkreli will get a grilling, though Schiller is the only one expected to answer any questions. Read more >>
Biotech pioneer Marc Tessier-Lavigne will take charge as Stanford University's next president starting September 1. Read more >>
POPULAR COMMENT THREADS
Not to be left on the sidelines, several pharma companies took to the airwaves Sunday for the biggest ad show of the year, also known as the Super Bowl. With one of the largest consumer audiences on TV, dozens of advertisers jockey to get their messages in the game, this year at an estimated $5 million per 30 seconds. Read more from FiercePharmaMarketing >>
It's not often that a disease-awareness campaign makes unwanted waves. But Novartis' recently launched heart failure push is doing just that--literally and figuratively.
Some of GlaxoSmithKline's prominent investors may be pushing for a four-way breakup of the company. But others are just fine preserving the status quo--and keeping CEO Andrew Witty at the helm to do it.
Big pharma knows that lawmakers are hopping mad over drug price increases. So the industry is launching an ad campaign to try to get back in politicians' good graces and repair its tarred image as the debate over drug pricing rages on.
Amgen's Repatha is in a market brawl with Sanofi and Regeneron's Praluent as the competitors rush to sew up as many OKs around the world as possible for the new-gen cholesterol fighters following their FDA approval last year within weeks of one another. Now Amgen has pulled ahead in England after the country's drug pricing watchdog has both changed course to cover Repatha for some patients, while dealing its competitors a blow with a rejection for Praluent.
Japan's efforts to cut drug costs have prompted at least one big deal this past year, with Takeda Pharmaceutical saying that it would team up with Teva Pharmaceutical Industries to respond to the country's generics push. These kind of deals will become more common, some analysts say, as Japan shifts away from branded meds and spurs development of low-cost copycats.
From Our Sister Sites
The government of Japan is changing the lucrative brand-name healthcare market as its population ages and requires more drugs with a push to make at least 80% of the government's drug spending be for generics.
Tokyo-based Eisai said it will start selling active pharmaceutical ingredients to domestic generic makers and will invest "tens of millions of dollars" to scale up production at its India plant in Andhra Pradesh.